Jazz Pharmaceuticals Aktie

par excellence https://www.ariva.de/jazz_pharmaceuticals-aktie/chart?t=year&boerse_id=207 Quelle_Chart:ariva.de https://www.investopedia.com/terms/c/cupandhandle.asp

Zitat:"Announces $5 billion revenue target for 2025.......Confirms 2021 revenue expected to be within previously announced guidance range, exceeding $3 billion Jazz Pharmaceuticals plc ........ today announced its Vision 2025 to deliver sustainable growth and enhanced value. Vision 2025 includes the following expectations: 1) generating $5 billion in revenue in 2025; 2) approval of at least five additional novel products by the end of the decade; and 3) realizing a 5% adjusted operating margin1 improvement from 2021 to 2025, driven by operational excellence. ............The Company also confirmed that it expects to meet its previously announced 2021 revenue guidance range of $3.02 to $3.1 billion and its net product sales guidance for neuroscience and oncology.....Jazz ended 2021 demonstrating executional excellence across its business, including launching five key products in 2020 and 2021, integrating the GW Pharmaceuticals business, making progress towards its deleveraging target and initiating multiple potentially registrational clinical trials. The Company remains on track to deliver revenue diversification, with at least 65% of 2022 net product revenue from newly launched or acquired products,3 driving sustainable growth and enhanced shareholder value...... "Building on our track record of strong execution and guided by our patient-centric approach, Jazz is setting forth its Vision 2025 to deliver meaningful treatment options to patients, a great place to work for employees and significant value to shareholders," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "Jazz's leadership in sleep and rare epilepsy with Xywav and Epidiolex, respectively, coupled with promising new oncology products like Zepzelca and Rylaz, have led to the rapid transformation of our revenue base....." ENDE Zitat Quelle:https://www.stockwatch.com/News/Item/U-prSF25540-U!JAZZ-20220110/U/JAZZ

https://nakedshortreport.com/company/JAZZ Sep 23 NA NA NA 500,635 311,673 62.26

Zitat:"BofA Virtual Global Healthcare Conference 2021 Cantor Virtual Global Healthcare Conference........ DUBLIN, Sept. 8, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming virtual investor conferences: BofA Virtual Global Healthcare Conference 2021 on Wednesday, September 15, 2021 The presentation will be available to registered conference attendees. Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021........."Ende Zitat Quelle:https://www.stockwatch.com/News/Item/U-prSF99752-U!JAZZ-20210908/U/JAZZ auf aktuellem Niveau kann man (rein subjektiv - keine Aufforderung zum Handeln - Hinweis auf die Gesamtmarkt Lage und Makroökonomischen - Pandemischen Faktoren)...IMO langsam einsammeln Kurse bewegen sich aktuell nahe 1-Jahrestief... nicht verifizierte Kursmarken - rein subjektiv $130 / $124 / $112 / $98 ... als Unterstützung(en) Worst-Case $64 (all-time Gap Frühjahr 2013)